Perioperative and Complication-Related Outcomes for Robotic-Assisted versus Open Radical Cystectomy: A Comparative NSQIP Analysis
Rishabh Kumar Simhal,Daniel P Simon,Kerith R Wang,Yash B. Shah,Brandon Havranek,James Ryan Mark,Thenappan Chandrasekar,Mihir S Shah,Costas D Lallas
DOI: https://doi.org/10.1089/end.2023.0279
2024-01-26
Journal of Endourology
Abstract:Radical cystectomy (RC) is standard of care for muscle-invasive bladder cancer, but it comes with significant perioperative risk. Currently, both open radical cystectomies (ORC) and RARC are frequently performed. Using newly available data from the American College of Surgeons National Surgical Quality Improvement Project (NSQIP), we aim to compare 30-day outcomes between patients who received ORC or RARC, representing one of the largest, most recent multi-institutional studies comparing these operative approaches. RC procedures performed between 2019-2021 were identified in NSQIP. Cases in the ORC group were planned open procedures, and cases in the RARC group were robotic-assisted, including unplanned conversion to open cases for intention-to-treat. Chi-square and t-tests were performed to compare baseline demographics and operative parameters. Multivariate analysis was performed for outcomes including major complications, minor complications, and 30-day mortality, while adjusting for baseline differences significant on univariate analysis. 5,343 RC cases were identified. Of these 70% underwent planned ORC while 30% received RARC. RARC was associated with longer operative times and shorter hospital length of stay compared to ORC. On multivariate analysis, there was no difference between the cohorts in 30-day rates of major complications, hospital readmissions, need for reoperation, or mortality. ORC was however associated with higher rates of minor complications, bleeding, superficial surgical site infections, and anastomotic leak. In the NSQIP database, ORC is associated with higher rates of 30- day minor complications, most notably bleeding, compared to RARC. However, there is no difference in regards to perioperative major morbidity or mortality. This study is unique in the size of the cohorts compared, the timeliness of the data (2019-2021), applicability to a variety of different practice settings across the country, and the ability to control for factors, such as type of urinary diversion, pathological bladder cancer staging, as well as use of neoadjuvant chemotherapy.
urology & nephrology